Update from London on the EACPT

The Executive Committee of the European Association for Clinical Pharmacology and Therapeutics (EACPT) met in London 12-13 October, hosted by the British
Pharmacological Society. The main business of this EC meeting was planning for major pending events and activities. Key items included:

Members of the EACPT Executive Committee

the 12th biennial EACPT congress to be held from 27-29 June 2015 in Madrid 
- the EACPT focus meeting in Nijmegen in the Netherlands, 3-5 July 2014 - the key theme is cardiovascular.
- update on the official EACPT journal Clinical Therapeutics (online access is a benefit for individual Associates of the EACPT - see register interest link below) 
- interaction with key policy organisations interested in medicines and patient safety, including the European Medicines Agency. EACPT chair Professor Gonzalo Calvo is inaugural co-chair of the Healthcare Professionals Working Party of the 

European Medicines Agency. 

The above photo, taking at the British Pharmacological Society offices, shows: 

Back row: Dinko Vitezić (Croatia), Simon Maxwell (UK), Donald Singer (UK), Ingolf Cascorbi (Germany), Ádám Vas (Hungary), Gerard Rongen (Netherlands) 

Front row: Gonzalo Calvo (Spain), Caridad Pontes (Spain), Marie Besson (Geneva), Ylva Böttiger (Sweden),  Caroline Samer (Geneva). 

Also at the meeting were Professor Kim Brosen (Denmark) and EACPT Chair-elect Professor Tabassome Simon (France).

Parliament buildings and former County Hall

EACPT biennial congresses provide excellent opportunities to showcase issues of topical international concern to the CPT community, through timely and accessible original research presentations and commentaries to policy-makers, health and industry professionals, health technology providers, patient groups and academia. 

The Madrid 2015 Congress will bring together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. 

Co-organisers Marie Besson and Caroline Samer reported on the recent Geneva EACPT Congress. Almost 600 delegates attended the 11th EACPT Congress in Geneva in August 2013, where there were 101 invited speakers from 21 countries - 15 countries from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. 330 abstracts were presented as oral and poster communications, following submissions from 57 countries from all 5 continents.

EACPT EC members Caridad Pontes (Spain), Adam Vaz (Hungary), Marie Besson (Switzerland) and Gonzalo Calvo (EACPT Chair: Spain) are members of the organizing committee for the 2015 EACPT Congress in Madrid. 

Key themes at the Madrid congress will include translational medicine and pharmacogenetics, advances in personalised diagnostics to improve the safety and effectiveness of medicines, updates on new biological approaches to disease, therapeutics of cardiovascular, cancer and inflammatory disease, clinical trial design and regulation, drug safety and toxicology, clinical trial design and governance, health policy and safe prescribing.

Register below interest in becoming an individual Associate of the EACPT and in future EACPT activities. 

EMA health professional working party elects EACPT's Gonzalo Calvo as its first co-chair

Gonzalo Calvo, chair of the European Association for Clinical Pharmacology and Therapeutics (EACPT), is the new co-chair of the HCPWP of the European Medicines Agency. 

Professor Calvo is a consultant in clinical pharmacology in Barcelona and has extensive experience both in medicines regulation, including nearly ten years as member of the Agency’s Committee for Medicinal Products for Human Use (CHMP), and in learned societies. This is the first time that the HCPWP has elected a co-chair, following its formal establishment in June 2013.  

The Patients' and Consumers' Working Party (PCWP) and the Healthcare Professionals' Working Party (HCPWP) of the European Medicines Agency (EMA) both elected their new co-chairs on 26th September, 2013.

David Haerry of the European AIDS TreatmentGroup (EATG) is the new co-chair of the PCWP. He has 15 years experience as an advocate for HIV patients’ rights and has been a member of the PCWP since 2006. He will replace Lise Murphy of the European Organisation for Rare Diseases (EURORDIS), who was co-chair of the PCWP since 2010 and whose mandate has come to an end. The PCWP was established in 2005.

Both David Haerry and Gonzalo Calvo will co-chair these working parties for the next three years, together with Isabelle Moulon, Head of Patients and Healthcare Professionals at the EMA.

The main role of the PCWP and the HCPWP is to provide recommendations to the EMA and its scientific committees on all matters of interest to either patients and consumers or healthcare professionals in relation to medicinal products, as well as to monitor interactions between the Agency and patients, consumers and healthcare professionals.

EACPT Executive Committee members Professor Donald Singer from the UK and Professor Ingolf Cascorbi from Germany are also members of the EMA Health Care Professionals Working Party.

Professor Simon Maxwell, co-chair of the EACPT Educational Subcommittee, is observer on behalf of the HCP-WP on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCPeP).

New European Medicines Agency advice on black triangle prompts for medicines monitoring

See full EMA Press Release

Adverse reactions to drugs and vaccine are common and may be serious, with the risk of leading to hospital admission, delayed discharge from hospital or death. It has been estimated that up to two-thirds of the ADRs may be preventable, or interrupted before they become severe. 

The European Medicines Agency (see press release link above) has introduced a new EU-wide scheme to improve reporting and prevention of new, unexpected and serious adverse reactions to drugs and vaccines. The scheme involves increased monitoring, including supported by a list of products identified by an inverted black triangle symbol: typically for products that are new, or have had a new indication or formulation approved, or for which serious concerns have been raised.

Communication materials on additional monitoring and the inverted black triangle symbol have been produced in all EU languages. For further details see the factsheet and video below and the EMA Press Release.

Factsheet

Video in English (with subtitles in all official EU languages)

To view subtitles, click on 'captions' at the foot of the viewing pane and select your language. You can also turn subtitles on and off and change the way they appear.

Video in English

Transcript of podcast by Tabassome Simon on Clinical Pharmacology and FAST-MI

Listen to podcast of Professor Tabassome Simon discussing Clinical Pharmacology and the FAST-MI Registry.

DS     I am in Geneva at the 11^th EACPT Congress with Professor Tabassome Simon.  

FAST-MI co-author Ziad Mallat with EACPT Chair-Elect Tabassome Simon & EACPT Secretary Donald Singer

Tabassome, would you comment on the ways in which your expertise as a Clinical Pharmacologist has contributed to the success of the Fast-MI Registry.

TS      Since I am a Clinical Pharmacologist, I would just focus on papers emerged from my interests as a clinical pharmacologist.

What is great about being all together in different fields, is talking together.  We have different visions of the same issue and that gives us really strength, our way of looking at disease and that is what clinical pharmacology is about. 

One example of which we are very proud was the paper that we did that was published in the New England Journal of Medicine regarding the impact of polymorphisms for metabolism and transporters ABCB1 and CYP2C19 onoutcomes for those who were receiving clopidogrel. 

That was the first paper that we did together, with another team from the United States who did a trial called Triton with prasugrel and clopidogrel.  Both papers were published in the New England Journal of Medicine and that was a huge hit in 2009.  Later on, several other papers were focussed on this genotyping process, including with the Plato trial with ticagrelor.

One further aspect that FAST-MI brought us [was recording] concomitant drugs which were usually not taken into account in registries, in particular for PPIs -  proton pump inhibitors. We had that [information] and so we could look also at the impact of drug interactions. We published that in Circulation.

Later on we did several papers with Ziad Mallat and other colleagues regarding the impact of lipases such as sPLA2, both [from studies] in blood but also [from studies of] Mendelian randomisation. The paper is in press actually, in the Journal of American College of Cardiology, and will be published soon. Another paper regarding BAFF targeting B cells will be published in Nature Medicine this year.

DS     Tabassome Simon, thank you very much.

Selected references from FAST-MI publications

Simon T., Verstuyft C., Mary-Krause M, Quteineh L., Drouet E., Meneveau N., Steg P.G., Ferrieres J., Danchin N., Becquemont L., for the French Registry of Acute ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009;360 : 363-75

Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, Khalife K, Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrières J, Danchin N; USIK USIC 2000 Investigators; FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998-1006.

Simon T, Steg Ph G, Gilard M, Blanchard D,  Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre Th, Drouet E , Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of PPI use, clopidogrel use and CYP2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the FAST-MI Registry; Circulation 2011, 123:474-482

Danchin N, Coste P, Ferrieres J, STEG G, Cottin Y, Blanchard D, Belle L, Ritz B, Kirkorian G, Angioi M, Sans Ph, Charbonnier B, Eltchaninoff H, Gueret P, Khalife K, Asseman Ph , Puel J, Cambou J-P, Simon T. A comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary PCI for ST segment elevation acute myocardial infarction. Circulation 2008; 118: 268-276

Lind L.†, Simon T. †, Johansson L., Kotti S., Hansen T.,Machecourt J., Ninio E., Tedgui A., Danchin N.,Hakan Ahlstrom, Mallat Z. Circulating levels of secretory- and lipoproteinassociated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J, 2012; 33:2946-54. †contributed equally to this work

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-30.

Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefèvre T, Durand E, Blanchard D, Simon T, Cambou JP, Danchin N.Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries. Eur Heart J. 2012;33(20):2535-43.

Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, Mallat Z.Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570-7

Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, Schiele F, Ferrari E, Drouet E, Grollier G, Danchin N. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther. 2011;90(4):561-7

Lim P, Moutereau S, Simon T, Gallet R, Probst V, Ferrieres J, Gueret P, Danchin N. Usefulness of Fetuin-A and C-Reactive Protein Concentrations for Prediction of Outcome in Acute Coronary Syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction. Am J Cardiol.2013;111:31-7

Hanssen M, Cottin Y, Khalife K, Hammer L, Goldstein P, Puymirat E, Mulak G, Drouet E, Pace B, Schultz E, Bataille V, Ferrières J, Simon T, Danchin N.  French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. Heart. 2012;98:699-705.

Puymirat E, Taldir G Aissaoui  N, Lemesle G., Lorgis L., Cuisset Th., Bourlard P., Maillier B., Ducrocq G. , Ferrieres J, Simon T, Danchin N. Use of Invasive Strategy In Non-ST-Elevation Myocardial Infarction Is a Major Determinant of Improved Long-Term Survival. The FAST-MI Registry. JACC Cardiovasc Interv 2012;5(9):893-902.

Belle L, Labarère J, Fourny M, Drouet E, Mulak G, Dujardin JJ, Vilarem D, Bonnet P, Hanssen M, Simon T, Ferrières J, Danchin N; French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction study investigators. Quality of care for myocardial infarction at academic and nonacademic hospitals. Am J Med. 2012;125(4):365-73.

Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, Simon T; for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction.  J Clin Endocrinol Metab. 2010;95:4993-5002

Danchin N,  Fauchier L, Marijon E, Barnay C, Furber A, Mabo Ph, Bernard P, Blanc JJ, Jouven X, Le Heuzey JY, Charbonnier B,  Ferrieres J,  Simon T . Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart 2010;96:1809-1814

Puymirat E, Aïssaoui N, Collet JP, Chaib A, Bonnet JL, Bataille V, Drouet E, Mulak G, Ferrières J, Blanchard D, Simon T, Danchin N. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. Int J Cardiol, 2011, Nov 10. [Epub ahead of print]

Puymirat E, Aïssaoui N, Coste P, Dentan G, Bataille V, Drouet E, Mulak G, Carrié D, Blanchard D, Simon T, Danchin N. Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients ≥75 Years of Age from the FAST-MI Registry. Am J Cardiol. 2011;108:755-9

Simon T, Mary-Krause M, Cambou JP, Hanania G., Guéret P., Lablanche JM, Blanchard D, Genès N, Vaur L, Danchin N on behalf of the USIC investigators. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women. Results from the French nation-wide USIC registries. Eur Heart J, 2006, 27 (11) : 1282-8.

Patrick Mismetti on clinical drug development of new anticoagulants

At the 11th EACPT Congress in Geneva, Professor Patrick Mismetti from St Etienne in France, in a podcast with EACPT Secretary Donald Singer discusses
- training in Clinical Pharmacology
- the contribution of Clinical Pharmacology to research on anticoagulants
- advantages and challenges to the use of new anticoagulant
Listen to the podcast with Patrick Mismetti on clinical drug development of new anticoagulants

Around 600 young and senior pharmacologists and other delegates from 5 continents were in Geneva at the end of August, for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT).

More about the 11th EACPT Congress in Geneva.

Paddle steamer by Hôtel de la Paix, Geneva

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The Geneva Congress brought together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. For the Geneva Congress, there were 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Around 300 abstracts from 57 countries from all 5 continents were presented as oral and poster communications.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm   

EACPT website

Posts by delegates from the 11th EACPT Congress in Geneva

Around 600 young and senior delegates from 5 continents were in Geneva at

Jet d'eau - Geneva

the end of August, for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 

See below blogs by international delegates on sessions at the 2013 EACPT Congress in Geneva.

 

Laura Wilkins, University of Warwick, UK

Professor Gunther Hartmann on Oligonucleotide-based Immunotherapy: On the first evening of the 11^th EACPT congress in Geneva, Professor Hartmann (Head of the BONFOR research committee at the University of Bonn) introduced congress participants to the world of oligonucleotide-based immunotherapy.

In simple terms, oligonucleotides are short, single-stranded nucleic acid (DNA/RNA) molecules. These synthetic molecules are synthesized to interact specifically, depending on their nucleotide sequence, with complementary nucleotide sequences found in the body.

Antiviral defence in humans relies heavily on the detection of the nucleic acids of invading viruses by Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). Having worked in the field of oligonucleotides since 1995, Gunther Hartman’s research has focused on the immunorecognition of synthetic nucleic acids.

In particular, the group discovered that short interfering RNA molecules (siRNAs) are recognised by TLRs in the human immune system. The activation of TLR7 was shown to activate the pathway for production of interleukin 1 beta, initiating an immune response.

The group’s research then focused on the understanding of RLR mechanisms, these receptors being found in the cytoplasm of all human cells. Two RLRs (RIG-I and MDA-5) induce an innate immune response when stimulated by pathogenic RNA. In this way, a synthetic oligonucleotide to activate such a receptor could serve to stimulate an inactive or deficient immune system, or possibly even as a vaccine to protect against a particularly virulent virus.

Professor Hartmann’s group worked to characterise the signalling pathways and the structure of the binding pocket of the antiviral cytosolic RIG-I, involved in innate response to the influenza virus. This led to the development of an oligonucleotide mimic of the identified 5’-triphosphate RNA ligand.

This mimic (CpG) is currently undergoing clinical trials. Interestingly, activation of RIG-I and MDA-5 also caused apoptosis (programmed cell death) in animal tumour models (in melanoma cells). This apoptosis was not seen in non-tumour cells, suggesting a use in anti-cancer therapy.

Professor Hartmann’s lecture showed us that current research in oligonucleotide-based immunotherapy and even cancer therapy could still only be just scratching the surface of further possible applications.

More about the 11th EACPT Congress in Geneva. 

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website

Highlights of the 2013 EACPT Congress in Geneva

Around 600 young and senior pharmacologists from 5 continents were in

Congress President Pierre Dayer with local organizers Caroline Samer and Marie Besson

Geneva for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 

Marie Besson with Heather Sheppard and Gaëlle Notzli from MCI

Key developments included
- a new journal affiliation with Clinical Therapeutics - the journal team attended

EACPT Chairman Gonzalo Calvo

the Congress and Editor-in-Chief Richard Shader gave a Masterclass on scientific publishing
- introduction of a new individual Associate membership category for EACPT - more news on how to join will follow 
- individual Associate membership will include online access to the official EACPT journal - Clinical Therapeutics.
- announcements of future EACPT Congresses for Madrid in 2015, Prague in 2017, and Stockholm in 2019. 

EACPT Awards

Sir Michael Rawlins and Carlo Patrono

- Lifetime achievement awards went to Professor Sir Michael Rawlins and to Professor Carlo Patrono.
- The EACPT Scientific Award went to Dr David Devos.
- A Special EACPT Award was presented to EACPT co-founder Professor Michael Orme and accepted on his behalf by fellow EACPT co-founder Professor Folke Sjöqvist.

EACPT Poster Prize winners

Moderated Poster Session

PP020 Domenico Italiano, Italy
Title: EFFECTS OF ARIPIPRAZOLE AND RISPERIDONE ON VENTRICULAR REPOLARIZATION IN CHILDREN AND ADOLESCENTS
 
PP114 Annemarie Thijs, Netherland
Title: SUNITINIB DOES NOT REDUCE ENDOTHELIUM-DEPENDENT VASODILATION IN HUMANS

PP219 Roselyne Boulieu, France
Title: THIOPURINE METABOLITES ARE USEFUL IN PREDICTING AZATHIOPRINE RESISTANCE IN PEDIATRIC IBD PATIENTS

PP233 Caroline Samer, Switzerland
Title: CYP1A ACTIVITY AFTER CHRONIC EXPOSURE TO DIOXINS FROM A WASTE INCINERATOR

More about the 11th EACPT Congress in Geneva

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The Geneva Congress brings together a wide range of international delegates,

Speaker Panel

including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. 

For the Geneva Congress, there are 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Around 400 abstracts from 57 countries from all 5 continents are being presented as oral and poster communications.

 

Social programme - on Lake Geneva

The EACPT was founded 20 years ago and now includes all national

Social programme - on Lake Geneva

organisations for clinical pharmacology in Europe. 

The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience.

The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Official EACPT journal: Clinical Therapeutics 

More about the 11th EACPT Congress in Geneva.

More about the EACPT.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm  

Tabassome Simon discusses Clinical Pharmacology and the FAST-MI Registry

At the 11th EACPT Congress in Geneva, EACPT Vice-Chairman Professor Tabassome Simon from Paris discussed results on inflammatory mediators and outcomes of acute coronary syndromes, based on data from the French FAST-MI Registry.
In a podcast discussion with EACPT Secretary Donald Singer, Tabassome Simon discusses- the origins and significance of the FAST-MI French Registry of patients with acute coronary syndromes
- the contribution of Clinical Pharmacology to the success of FAST-MI 
- the strengths of including non-cardiological drugs in FAST-MI
- the strengths of bio-banking serological and genetic samples in FAST-MI

1. Listen to the podcast with Tabassome Simon about the origins and importance of the FAST-MI Registry.

2. Listen to Tabassome Simon discussing the role of Clinical Pharmacology in FAST-MI Registry.  Download transcript

FAST-MI collaborator Ziad Mallat with EACPT Vice-Chair Tabassome Simon and EACPT Secretary Donald Singer

Weblinks for selected FAST-MI publications


Around 600 young and senior pharmacologists and other delegates from 5 continents were in Geneva at the end of August, for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 

More about the 11th EACPT Congress in Geneva.

Paddle steamer by Hôtel de la Paix, Geneva

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The Geneva Congress brought together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. For the Geneva Congress, there were 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Around 300 abstracts from 57 countries from all 5 continents were presented as oral and poster communications.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm  

EACPT Journal Matters - Clinical Therapeutics at the 2013 EACPT Geneva Congress

The team from the EACPT official journal were in Geneva for the 11th EACPT

Terry Materese, Judy Pachella and Richard Shader

Congress. This provided a great opportunity for EACPT members and congress delegates to find out more about the journal from the Editor Richard Shader, and leading members of the publishing team: Executive Publisher, Terry Materese, and Managing Editor, Judy Pachella. 

It also provided an excellent forum for the Editor-in-Chief, Richard Shader to provide a Masterclass on how to publish a scientific paper.

Initial fruits of collaboration between EACPT and Clinical Therapeutics
-  publications in the journal pending for articles from EACPT Lifetime Award

EACPT International Editor Donald Singer with Carlo Patrono

EACPT International Editor Donald Singer with Sir Michael Rawlins

winners Carlo Patrono and Sir Michael Rawlins, from EACPT Scientific Award winner David Devos, and further content from the Congress, including Congress Abstracts online.

View and download Congress Programme.

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The European Association of Clinical Pharmacology and Therapeutics has  Clinical Therapeutics as its Official Journal, in partnership with the major international publisher Elsevier. 

The journal since April 2013 features highlights of EACPT scientific and other activities and provides information on future EACPT congresses, summer schools and other events. The journal will also publish peer-reviewed original papers and reviews arising from EACPT conferences.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm 

EACPT website http://eacpt.org